Related references
Note: Only part of the references are listed.Periaqueductal gray is required for controlling chronic stress-induced depression-like behavior
Wei-Hao Peng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2022)
Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial
Cerena Miravalles et al.
TRIALS (2022)
Neurobiology of Depression: Chronic Stress Alters the Glutamatergic System in the Brain-Focusing on AMPA Receptor
Ming Tatt Lee et al.
BIOMEDICINES (2022)
Involvement of Scratch2 in GalR1-mediated depression-like behaviors in the rat ventral periaqueductal gray
Yutao Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray
Po-Sheng Yang et al.
NEUROPHARMACOLOGY (2020)
Additive interaction between scopolamine and nitric oxide agents on immobility in the forced swim test but not exploratory activity in the hole-board
Mohammad Nasehi et al.
PSYCHOPHARMACOLOGY (2019)
Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine
Kenichi Fukumoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Periaqueductal Gray Glutamatergic Transmission Governs Chronic Stress-Induced Depression
Yu-Cheng Ho et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine
Sriparna Ghosal et al.
BIOLOGICAL PSYCHIATRY (2018)
(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray
Dylan Chou et al.
NEUROPHARMACOLOGY (2018)
GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine
Rong-Jian Liu et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Ronald S. Duman et al.
NATURE MEDICINE (2016)
Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures
Ashley E. Lepack et al.
NEUROPHARMACOLOGY (2016)
Impairment of adenylyl cyclase-mediated glutamatergic synaptic plasticity in the periaqueductal grey in a rat model of neuropathic pain
Yu-Cheng Ho et al.
JOURNAL OF PHYSIOLOGY-LONDON (2015)
Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors
Andrea Navarria et al.
NEUROBIOLOGY OF DISEASE (2015)
BDNF Release Is Required for the Behavioral Actions of Ketamine
Ashley E. Lepack et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
Descending modulation of pain: the GABA disinhibition hypothesis of analgesia
Benjamin K. Lau et al.
CURRENT OPINION IN NEUROBIOLOGY (2014)
Antidepressant treatment history as a predictor of response to scopolamine: clinical implications
Jessica S. Ellis et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Neurobiology of Rapid Acting Antidepressants: Role of BDNF and GSK-3β
Ronald S. Duman et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses
Bhavya Voleti et al.
BIOLOGICAL PSYCHIATRY (2013)
Changes in the Cholinergic System between Bipolar Depression and Euthymia as Measured with [123I]5IA Single Photon Emission Computed Tomography
Jonas O. Hannestad et al.
BIOLOGICAL PSYCHIATRY (2013)
Antidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review
Wayne C. Drevets et al.
BIOLOGICAL PSYCHIATRY (2013)
Pulsed Intravenous Administration of Scopolamine Produces Rapid Antidepressant Effects and Modest Side Effects
Maura L. Furey et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Hypofunction of Glutamatergic Neurotransmission in the Periaqueductal Gray Contributes to Nerve-Injury-Induced Neuropathic Pain
Yu-Cheng Ho et al.
JOURNAL OF NEUROSCIENCE (2013)
Persistent β2*-Nicotinic Acetylcholinergic Receptor Dysfunction in Major Depressive Disorder
Aybala Saricicek et al.
AMERICAN JOURNAL OF PSYCHIATRY (2012)
Activation of Orexin 1 Receptors in the Periaqueductal Gray of Male Rats Leads to Antinociception via Retrograde Endocannabinoid (2-Arachidonoylglycerol)-Induced Disinhibition
Yu-Cheng Ho et al.
JOURNAL OF NEUROSCIENCE (2011)
Serendipity Strikes Again: Scopolamine as an Antidepressant Agent in Bipolar Depressed Patients
David S. Janowsky
CURRENT PSYCHIATRY REPORTS (2011)
Antidepressant Drug Effects and Depression Severity A Patient-Level Meta-analysis
Jay C. Fournier et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women Than in Men
Maura L. Furey et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature
Noah S. Philip et al.
PSYCHOPHARMACOLOGY (2010)
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Nanxin Li et al.
SCIENCE (2010)
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis
Yann S. Mineur et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Positive AMPA Receptor Modulation Rapidly Stimulates BDNF Release and Increases Dendritic mRNA Translation
Hussam Jourdi et al.
JOURNAL OF NEUROSCIENCE (2009)
Muscarinic Modulation of Synaptic Transmission via Endocannabinoid Signalling in the Rat Midbrain Periaqueductal Gray
Benjamin K. Lau et al.
MOLECULAR PHARMACOLOGY (2008)
Antidepressant efficacy of the antimuscarinic drug scopolamine - A randomized, placebo-controlled clinical trial
Maura L. Furey et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
The epidemiology of major depressive disorder - Results from the National Comorbidity Survey Replication (NCS-R).
RC Kessler et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Share Paper
